Inhibition of Aβ(1-40) fibril formation by cyclophilins
Marten Villmow1, Monika Baumann2, Miroslav Malesevic3
1Max Planck Research Unit for Enzymology of Protein Folding, Weinbergweg 22, D-06120 Halle (Saale), Germany.
Abstract:
Cyclophilins interact directly with the Alzheimer's disease peptide Aβ (amyloid β-peptide) and are therefore involved in the early stages of Alzheimer's disease. Aβ binding to CypD (cyclophilin D) induces dysfunction of human mitochondria. We found that both CypD and CypA suppress in vitro fibril formation of Aβ(1-40) at substoichiometric concentrations when present early in the aggregation process. The prototypic inhibitor CsA (cyclosporin A) of both cyclophilins as well as the new water-soluble MM258 derivative prevented this suppression. A SPOT peptide array approach and NMR titration experiments confirmed binding of Aβ(1-40) to the catalytic site of CypD mainly via residues Lys(16)-Glu(22) The peptide Aβ(16-20) representing this section showed submicromolar IC50 values for the peptidyl prolyl cis-trans isomerase activity of CypD and CypA and low-micromolar KD values in ITC experiments. Chemical cross-linking and NMR-detected hydrogen-deuterium exchange experiments revealed a shift in the populations of small Aβ(1-40) oligomers towards the monomeric species, which we investigated in the present study as being the main process of prevention of Aβ fibril formation by cyclophilins.
Insights
Cyclophilins, including CypD and CypA, prevent amyloid beta fibril formation in early Alzheimer's disease stages. They bind to amyloid beta, shifting oligomers to monomers, thus inhibiting aggregation.
Area of Science:
- Biochemistry
- Neuroscience
- Molecular Biology
Background:
- Cyclophilins interact with amyloid beta (Aβ) peptides, implicating them in early Alzheimer's disease.
- Aβ binding to cyclophilin D (CypD) can lead to mitochondrial dysfunction.
Purpose of the Study:
- To investigate the role of cyclophilins (CypD and CypA) in the in vitro fibril formation of Aβ(1-40).
- To elucidate the mechanism by which cyclophilins inhibit Aβ aggregation.
Main Methods:
- In vitro fibril formation assays.
- SPOT peptide array and NMR titration experiments to confirm Aβ binding to CypD.
- Isothermal titration calorimetry (ITC) to determine binding affinity.
- Chemical cross-linking and NMR-detected hydrogen-deuterium exchange experiments.
Main Results:
- CypD and CypA significantly suppressed Aβ(1-40) fibril formation at substoichiometric concentrations when added early.
- Cyclophilin inhibitors (CsA and MM258) prevented this suppression.
- Aβ(1-40) binds to the catalytic site of CypD, primarily through residues Lys(16)-Glu(22).
- Aβ(16-20) peptide showed submicromolar IC50 and low-micromolar KD values for CypD and CypA.
- Cyclophilins promote a shift from small Aβ(1-40) oligomers to monomeric species, inhibiting fibril formation.
Conclusions:
- Cyclophilins actively inhibit Aβ(1-40) fibril formation by preventing oligomerization.
- The interaction occurs at the catalytic site of cyclophilins, involving specific Aβ residues.
- This mechanism offers a potential therapeutic target for Alzheimer's disease by modulating Aβ aggregation.
More Related Videos
06:27Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy
Published on: November 30, 2018
10:24A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources
Published on: January 27, 2026
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Actin Filament Depolymerization
In F-actin, the ADF/cofilin proteins...
Inhibitors of Bacterial DNA Synthesis
